Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PatientView

Brexit: the facts (and the alternative facts)

How Brexit affects pharma

- PMLiVE

Lucid Group Achieve UK’s Highest Award for Business Success

Lucid Group have been chosen to receive a Queen’s Award for Enterprise in International Trade. This award is widely regarded as the UK’s highest accolade for business success and they...

Lucid Group Communications Limited

- PMLiVE

Brexit: Implications for the pharma industry

From patents to the EMA, data protection to clinical trials, there's a lot that should be a concern

Can UK pharma rise to the post-Brexit challenge?

Our dominant and thriving industry is one we should be proud of

Top tips for “digitally cautious” pharma

Some practical ways to enter this new era of customer and patient-centricity

- PMLiVE

Pharma’s reputation on the wane, say patient groups

Survey outlines their demands that the industry "must do better" for its patients

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

Marketing strategy in complex environments

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what...

Blue Latitude Health

- PMLiVE

Stress testing for the perfect compliance storm

...as governments and regulators impose new legislation and strengthen their compliance regimes

- PMLiVE

Artificial intelligence: could pharma lead the way?

Producing powerful, relevant user experiences will be one key area to target

- PMLiVE

Framing the issues

When access to healthcare isn't access

Cell and gene therapies: on course for commercial success?

Funding and reimbursement of cell and gene therapies pose a major challenge as payers consider how to evaluate a commercial proposition that is completely divergent from the traditional pharmaceutical model....

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links